Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) reported significant clinical improvements in the second Expanded Access patient (EA2) with non-active secondary progressive multiple sclerosis (SPMS) after using intranasal foralumab. The patient's Expanded Disability Status Scale (EDSS) score improved from 6.0 to 5.0 since January 2022. The principal investigator emphasized that such improvements in non-active SPMS patients are rare and warrant further Phase 2 trials. Tiziana is prioritizing intranasal foralumab due to promising results, with six patients currently enrolled in the program.

Tiziana Life Sciences (NASDAQ: TLSA) reported its interim results for the six months ending June 30, 2022, highlighting significant developments in its clinical trials and business activities. The FDA approved the enrollment of two more patients for intranasal foralumab under the Expanded Access Program, with promising clinical outcomes showcased. However, a Phase 1b trial for Crohn's disease is on hold, impacting future research timelines. Financially, the company posted a loss of $8.3 million, a decrease from the previous year's $17 million loss, but its cash reserves fell to $26.5 million from $42.2 million, raising concerns over sustainability.

Tiziana Life Sciences Ltd (NASDAQ: TLSA) reported interim results for the six months ending June 30, 2022, highlighting advancements in its therapeutic pipeline for oncology and immune diseases. The company achieved FDA approvals for expanded patient access to its foralumab treatment for Secondary Progressive Multiple Sclerosis (SPMS) and initiated Phase 1b clinical trials in Crohn’s disease. Financially, Tiziana reported a loss of $8.3 million, down from $17.0 million in the prior year, with $26.5 million in cash reserves. Research and development expenses increased to $7.5 million, reflecting continued investment in key programs.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its participation at the Biotech Showcase and LifeSci Corporate Access Event on January 9-10, 2023, in San Francisco. The Chief Medical Officer, Dr. Matthew Davis, will host institutional investor meetings and present at both events. The Biotech Showcase presentation is scheduled for January 10, 2023, at 11:00 am PT. Tiziana focuses on developing immunomodulation therapies via innovative drug delivery methods, with lead candidates intranasal foralumab and milciclib showing promising clinical results.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) has completed the in-life phase of a 13-week preclinical study on its intranasal foralumab in transgenic HuGEMM CD3 mouse models. The study confirmed that doses up to 50 µg/rodent were well tolerated, with no adverse clinical changes or related fatalities observed. This milestone is crucial for Tiziana as it supports their upcoming FDA Phase 2 meeting request to study foralumab in conditions such as Multiple Sclerosis and Alzheimer’s Disease. Feedback from the FDA is expected in Q1 2023.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) received a 180-day extension from Nasdaq to comply with the minimum bid price rule, now due by June 12, 2023. Initially notified on June 14, 2022, the company had until December 12, 2022, to rectify its bid price deficiency. The extension allows the stock to continue trading on the Nasdaq Capital Market, and compliance can be regained if the stock closes at or above $1.00 per share for ten consecutive business days. Tiziana is focused on developing innovative CNS immunomodulation therapies.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its 2022 Annual General Meeting scheduled for December 29, 2022. Shareholders must vote by the record date of November 30, 2022. Relevant documents, including the agenda and financial statements, have been sent via mail and are available on the company's website. Tiziana is a clinical-stage biopharmaceutical firm focusing on innovative drug delivery methods for immunotherapy. Its lead candidates include the intranasal foralumab and milciclib, which have shown promising safety and efficacy in clinical studies.

Tiziana Life Sciences (Nasdaq: TLSA) announced that research published in Frontiers in Immunology supports its intranasal foralumab as a promising treatment for autoimmune and CNS diseases. Conducted by Brigham and Women's Hospital and Harvard Medical School, the study involving 27 volunteers demonstrated a favorable safety profile with no adverse events across doses of 10ug, 50ug, and 250ug. Notably, immunological effects peaked at the 50ug dosage, showing potential for future clinical applications without the side effects common in IV anti-CD3 treatments.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced a corporate update focusing on the development of intranasal foralumab for CNS inflammatory diseases. The company aims to prioritize resources for this therapeutic candidate, leveraging positive preclinical results. Upcoming milestones include results from PET scans for patients with non-active secondary-progressive Multiple Sclerosis expected in Q1 2023, and plans for an FDA Type C meeting regarding its Phase 2 program. Tiziana has sufficient capital to fund developments until Q1 2024.